Phase 3Recruiting
Diabetic Peripheral Pain Coexisting with Vitamin B12 deficiency to treat with FDC of Pregabalin plus Methylcobalamin plus Duloxetine (Delayed Release) Capsules.
A Multicentric, Randomized, Double Blind, Double Dummy, Prospective, Parallel Group, Comparative, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of FDC of Pregabalin plus Methylcobalamin plus Duloxetine (Delayed Release) Capsules Versus FDC of Pregabalin plus Methylcobalamin plus Nortriptyline Tablets in Subjects with Diabetic Peripheral Neuropathic Pain Coexisting with Vitamin B12 Deficiency. - NIL
- Sponsor
- Ravenbhel Healthcare Pvt. Ltd. (Industry)
- Enrollment
- 210 planned
- Conditions
- Health Condition 1: E114- Type 2 diabetes mellitus with neurological complications
- Interventions
- FDC of Pregabalin 75 mg plus Methylcobalamin 1500 mcg plus Duloxetine DR 20 mg Capsule and Matching Placebo Tablet
- Registry
- CTRI-2024-01-062147
Full record on the Clinical Trials Registry – IndiaSource: WHO ICTRP, processed April 29, 2024
Primary outcomes
- Mean change in visual analog scale (VAS) from baseline to end of the treatment. (12 weeks)Timepoint: 12 weeks
History
Last registry update
Started
Registered